SecBot SecBot
8-K ·Filed Nov 3, 2026

PFE

PFIZER INC
BULLISH
Impact 6/10
Horizonweeks Processed13d 13h ago SEC0000078003-26-000125
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The guidance raise and strong beat on both EPS and revenue suggest accelerating momentum in the core non-COVID portfolio. Watch for continued execution on the cost realignment program and pipeline catalysts including berobenatide Phase 3 starts and Talzenna/Tukysa label expansions.

DirectionBullish
Confidencehigh
Horizonweeks

Drugs in focus

PFE drug pipeline →

Abrysvo

● Neutral Named in this 8-K
Impact
Phase
Approved
Time to market
Already approved and commercially available since mid-2023.
Next catalyst
None dated

What to watchAbrysvo has no upcoming PDUFA dates or pivotal readouts; it is an approved, commercial product. Watch Pfizer's quarterly earnings reports for Abrysvo sales trends, particularly during the fall RSV season (September-January). The key competitive dynamic to monitor is whether Abrysvo can gain market share from GSK's Arexvy following its broader adult label (18-59 at-risk) and whether the GBS warning materially impacts uptake.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$30.00
T+0 close · Nov 3, 2026 · via day close
Latest settled
−2.13%
T+5 · $29.36 · next T+20 in 15d
Vs SPY
−1.55%
α at T+5
Latest observation
−2.00%
T+8 · FF3 residual α
  1. T+0 · Nov 3 $30.00entry
  2. T+1 · 13d ago +2.63%α +0.98% · $30.79
  3. T+5 · 7d ago −2.13%α −1.55% · $29.36
  4. T+9 · todayOpen
  5. T+20 · in 15d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pfizer reported Q3 2026 adjusted diluted EPS of $0.87, beating the $0.73 consensus by 19.2%, on revenue of $16.58B versus the $15.88B estimate. The company raised full-year 2026 revenue guidance by $1.5B at the midpoint to $62.0-$64.0B and raised/narrowed adjusted EPS guidance to $2.95-$3.05, reflecting strong year-to-date performance and confidence in the business.

Key Financial Metrics

EPS (Adj.)
$0.87
est $0.73 · +19.2% · GAAP: $0.56
Revenue
$16.6B
est $15.9B · +4.4% · 0.0% YoY
Rating
strong beat
Guidance
$62.0B to $64.0B
raised
Gross Margin
24.3%

Key Facts

  • Q3 2026 adjusted diluted EPS of $0.87 beat consensus of $0.73 by 19.2%
  • Q3 2026 revenue of $16.58B was above the $15.88B consensus estimate
  • Full-year 2026 revenue guidance raised by $1.5B at the midpoint to $62.0-$64.0B
  • Full-year 2026 adjusted diluted EPS guidance raised and narrowed to $2.95-$3.05 from $2.80-$3.00
  • Non-COVID product revenue grew 7% operationally; launched and acquired products grew 32% operationally
  • Eliquis revenue up 25% operationally, Padcev up 55%, Vyndaqel family up 12%, Lorbrena up 43%
  • Paxlovid revenue declined 63% operationally, Comirnaty down 29%, Prevnar family down 10%
  • Cecile Guegan appointed CFO and EVP effective November 1, 2026
  • No share repurchases completed in 2026; $3.3B remaining authorization

Financial Impact

Q3 adjusted EPS of $0.87 vs consensus $0.73; revenue $16.58B vs consensus $15.88B; FY guidance raised by $1.5B at midpoint for revenue and $0.10 at midpoint for adjusted EPS

revenueepsguidance

Segment Breakdown

SegmentRevenueGrowth
Primary Care$7.0B-9.0%
Oncology$4.3B+10.0%
Specialty Care$3.3B+7.0%
Hospital and Biosimilars$1.6B+2.0%
Pfizer CentreOne$300.0M-13.0%

Risk Factors

  • COVID-19 product revenue continues to decline (Paxlovid -63%, Comirnaty -29%)
  • Prevnar family revenue down 10% on lower vaccination rates and market share erosion
  • RD spending increased 18% operationally, pressuring margins
  • Restructuring charges of $791M in Q3 reflect ongoing cost realignment program
  • Generic/biosimilar competition expected to impact revenue by approximately $1.1B in 2026

Market Snapshot

Price
$30.65
Volume
740
Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
38% bullish (34 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000078003-26-000125
Document: pfe-20261103.htm0000078003-26-000125
Document: 0000078003-26-000125-index-headers.html0000078003-26-000125
Document: 0000078003-26-000125-index.html0000078003-26-000125
Document: 0000078003-26-000125.txt0000078003-26-000125
8-K Data (Synthetic)0000078003-26-000125

Track record

21 reports on PFE

Performance horizon

5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +17.28% at T+60 after the Aug 4, 2026 report. 6 of 8 went positive at some point.

Filters
  1. Nov 3, 202613d ago 8-K Neutral 2/10 Entry $30.79 Now $28.89 −6.17% settles Feb 2
  2. Nov 3, 202613d ago 8-K Bullish 6/10 Viewing Entry $30.00 Now $28.89 −3.70% settles Feb 1
  3. Oct 30, 202618d ago Court Ruling Neutral 2/10 Entry $30.67 Now $28.89 −5.80% settles Jan 29
  4. Oct 23, 202624d ago Institutional Cluster Mixed 3/10 Entry $30.03 Now $28.89 −3.80% settles Jan 21
  5. Aug 13, 202613w ago Court Ruling Neutral 1/10 Entry $26.79 to $29.23 Now $28.89 +7.84% ▲ +9.11% +12.15% vs SPY
  6. Aug 12, 202613w ago Insider Buy Bullish 5/10 Entry $26.80 to $29.39 Now $28.89 +7.80% ▲ +9.66% +15.14% vs SPY
  7. Aug 12, 202613w ago Insider Cluster Bullish 6/10 Entry $26.80 to $29.39 Now $28.89 +7.80% ▲ +9.66% +15.14% vs SPY
  8. Aug 6, 202614w ago Insider Cluster Bullish 4/10 Entry $26.20 to $30.52 Now $28.89 +10.27% ▲ +16.49% +18.16% vs SPY
  9. Aug 5, 202614w ago Insider Buy Bullish 5/10 Entry $26.20 to $30.52 Now $28.89 +10.27% ▲ +16.49% +18.16% vs SPY
  10. Aug 5, 202614w ago Insider Cluster Neutral 3/10 Entry $26.20 to $30.52 Now $28.89 +10.27% ▲ +16.49% +18.16% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens Wed (12h 7m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 3, 2026